Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Trubion Pharmaceuticals Inc. said Monday that its partner Pfizer Inc. is ending development of one experimental rheumatoid arthritis drug, but will keep studying a second therapy.
The Seattle company said Pfizer decided to stop development of the drug after it failed to meet its goal in a mid-stage clinical trial.
The study compared a drug designated TRU-015, or PF-05212374, to a placebo. Trubion said a combination of TRU-015 and methotrexate did not work better than the placebo and methotrexate in treating the disease.
Trubion said New York-based Pfizer will continue to develop a different rheumatoid arthritis drug called SBI-087 or PF-05230895.
On Monday, Trubion shares lost 6 cents to close at $3.66. Pfizer stock added 9 cents in extended trading to $15.42.